Depressive Disorder and Anxiety Disorders Clinical Trial
Official title:
A Randomised, Placebo-controlled, Double-dummy, Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GSK561679 and Lorazepam (Comparator) in Healthy Subjects
This study will be conducted in healthy volunteers to investigate the effect of single dose GSK561679 on the changes of brain activation, as it compares to an active comparator, lorazepam.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00536679 -
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
|
Phase 1 | |
| Completed |
NCT01424384 -
Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic
|
Phase 1 | |
| Completed |
NCT00426608 -
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
|
Phase 1 | |
| Completed |
NCT01031186 -
First Time in Human Study
|
Phase 1 | |
| Completed |
NCT00435695 -
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
|
Phase 1 | |
| Completed |
NCT00343707 -
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
|
Phase 2 | |
| Completed |
NCT01059591 -
First Study in Humans With GSK424887
|
Phase 1 | |
| Completed |
NCT01059578 -
First Study in Humans With GSK206136
|
Phase 1 | |
| Completed |
NCT00703547 -
A First Time in Human Study of GSK586529 in Healthy Volunteers
|
Phase 1 |